Skip to main content
Browse topics  Search all clinical trials

Clinical trials : hepatology

Showing 1 -10 of 20 results
This study will analyze gene mutations in liver cancer detected in patients with hepatitis C treatment.

Sandra Atlas Bass Center for Liver Diseases | 400 Community Drive | Manhasset | NY 11030
This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of emricasan in improving event-free survival based on a composite clinical endpoint (where all-cause mortality, new decompensation events, and MELD score progression are events) in subjects with decompensated NASH cirrhosis.

Sandra Atlas Bass Center for Liver Diseases | 400 Community Drive | Manhasset | NY 11030
This Phase 3b, open-label, non-randomized study will evaluate the efficacy and safety of Glecaprevir/Pibrentasvir (GLE/PIB) for 8, 12, or 16 weeks in in participants with chronic hepatitis C virus (HCV) genotype (GT) 1 - 6 infection with or without compensated liver cirrhosis and with chronic renal impairment in both HCV treatment-naïve and prior treatment-experienced participants.

Sandra Atlas Bass Center for Liver Diseases | 400 Community Drive | Manhasset | NY 11030
The study will enroll well-compensated cirrhotic as well as non-cirrhotic subjects treatment experienced with an NS5a Inhibitor + sofosbuvir and will include patients who did not complete the prescribed duration due to adverse event or any reason other than for non/poor compliance...

Sandra Atlas Bass Center for Liver Diseases | 400 Community Drive | Manhasset | NY 11030
An 8-week, dose ranging, open label, randomized, Phase 2 study with an 18-week extension, to evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)

Sandra Atlas Bass Center for Liver Diseases | 400 Community Drive | Manhasset | NY 11030
A multi-part study to assess safety, tolerability and efficacy of tropifexor (LJN452) in patients with primary biliary cholangitis

Sandra Atlas Bass Center for Liver Diseases | 400 Community Drive | Manhasset | NY 11030
The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic steatohepatitis (NASH) and fibrosis.

Sandra Atlas Bass Center for Liver Diseases | 400 Community Drive | Manhasset | NY 11030
The primary objective of the study is to compare the effect of daily oral administration of elafibranor 80mg and 120 mg on change in serum alkaline phosphatase (ALP) to that of placebo in patients with PBC and inadequate response to Ursodeoxycholic acid (UDCA).

Sandra Atlas Bass Center for Liver Diseases | 400 Community Drive | Manhasset | NY 11030
The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce progression to cirrhosis and associated complications in adults with NASH and bridging (F3) fibrosis.

Sandra Atlas Bass Center for Liver Diseases | 400 Community Drive | Manhasset | NY 11030
The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce associated complications in adults with cirrhosis due to NASH.

Sandra Atlas Bass Center for Liver Diseases | 400 Community Drive | Manhasset | NY 11030